Skip to main content
Top
Published in: International Journal of Hematology 2/2011

01-08-2011 | Original Article

Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome

Authors: Tohru Inaba, Yoichi Yuki, Soichi Yuasa, Naohisa Fujita, Kazue Yoshitomi, Toshinori Kamisako, Kunio Torii, Toshiharu Okada, Yoshimasa Urasaki, Takanori Ueda, Kaoru Tohyama

Published in: International Journal of Hematology | Issue 2/2011

Login to get access

Abstract

We evaluated the diagnostic utility of peripheral blood neutrophil distribution patterns obtained using the CELL-DYN SAPPHIRE hematology analyzer in patients with myelodysplastic syndrome (MDS). Peripheral blood was obtained from 467 individuals including 32 patients with MDS, and the respective neutrophil distribution patterns were observed using two light scatters [7-degree complexity (7D) and 90-degree lobularity (90D)]. These scattering intensities are shown as median (median neutrophil distribution: MND) and coefficient of variation (neutrophil distribution width: NDW). Generally, MDS patients showed lower 7D MND, higher 7D NDW, lower 90D MND and higher 90D NDW than other comparable groups. Whereas 90D parameters were more diagnostically efficient than 7D ones in patients with MDS. The sensitivity and specificity of 90D MND for MDS patients became 78.1 and 78.9%, respectively (cut-off value = 14,514). 90D NDW was most diagnostically effective with 87.5% sensitivity and 91.0% specificity (cut-off value = 21.2%). Both 90D parameters showed no evident correlation with the degree of either leukocytopenia or peripheral blood dysgranulopoiesis. In conclusion, neutrophil distribution parameters, especially 90D NDW, appear to provide convenient and objective markers for the screening of patients with MDS in routine laboratory hematology.
Literature
1.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRefPubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRefPubMed
2.
go back to reference Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 88–93. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 88–93.
3.
go back to reference Grrenberg P, Cox C, Le Beau MM, Fenaux P, Mrel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88. Grrenberg P, Cox C, Le Beau MM, Fenaux P, Mrel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
4.
go back to reference Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res. 2007;31:427–34.CrossRefPubMed Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res. 2007;31:427–34.CrossRefPubMed
5.
go back to reference Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.CrossRefPubMed Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.CrossRefPubMed
6.
go back to reference Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009;39:548–53.CrossRefPubMed Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009;39:548–53.CrossRefPubMed
7.
go back to reference Frisch B, Bartl R. Minimal diagnostic criteria for the myelodysplastic syndrome (MDS) in clinical practice. Leuk Res. 1992;16:6–8.CrossRefPubMed Frisch B, Bartl R. Minimal diagnostic criteria for the myelodysplastic syndrome (MDS) in clinical practice. Leuk Res. 1992;16:6–8.CrossRefPubMed
8.
go back to reference Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Murohashi I, Bessho M, et al. New system for assessing the prognosis of refractory anemia patients. Leukemia. 1999;13:1727–34.CrossRefPubMed Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Murohashi I, Bessho M, et al. New system for assessing the prognosis of refractory anemia patients. Leukemia. 1999;13:1727–34.CrossRefPubMed
9.
go back to reference Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol. 1996;33:177–85.PubMed Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol. 1996;33:177–85.PubMed
10.
go back to reference Bourner G, Dhaliwal J, Sumner J. Performance evaluation of the latest fully automated hematology analyzers in a large, commercial laboratory setting: a 4-way, side-by-side study. Lab Hematol. 2005;11:285–97.CrossRefPubMed Bourner G, Dhaliwal J, Sumner J. Performance evaluation of the latest fully automated hematology analyzers in a large, commercial laboratory setting: a 4-way, side-by-side study. Lab Hematol. 2005;11:285–97.CrossRefPubMed
11.
go back to reference Kang SH, Kim HK, Ham CK, Lee DS, Cho HI. Comparison of four hematology analyzers, CELL-DYN Sapphire, ADVIA 120, Coulter LH 750, and Sysmex XE-2100, in terms of clinical usefulness. Int J Lab Hematol. 2008;30:480–6.PubMed Kang SH, Kim HK, Ham CK, Lee DS, Cho HI. Comparison of four hematology analyzers, CELL-DYN Sapphire, ADVIA 120, Coulter LH 750, and Sysmex XE-2100, in terms of clinical usefulness. Int J Lab Hematol. 2008;30:480–6.PubMed
12.
go back to reference Yuki Y, Nishimura H, Saito J, Yamane Y, Nagata T, Yuasa S, et al. Screening of morphological abnormalities in myelodysplastic syndrome using CELL DYNE 3500 hematology analyzer. Jpn J Med Technol. 2009;58:821–6 (abstract in English). Yuki Y, Nishimura H, Saito J, Yamane Y, Nagata T, Yuasa S, et al. Screening of morphological abnormalities in myelodysplastic syndrome using CELL DYNE 3500 hematology analyzer. Jpn J Med Technol. 2009;58:821–6 (abstract in English).
13.
go back to reference Müller R, Mellors L, Johannessen B, Aarsand AK, Kiefer P, Hardy J, et al. European multi-center evaluation of the Abott Cell-Dyn sapphire hematology analyzer. Lab Hematol. 2006;12:15–31.CrossRefPubMed Müller R, Mellors L, Johannessen B, Aarsand AK, Kiefer P, Hardy J, et al. European multi-center evaluation of the Abott Cell-Dyn sapphire hematology analyzer. Lab Hematol. 2006;12:15–31.CrossRefPubMed
14.
go back to reference Hedberg P, Lehto T. Aging stability of complete blood count and white blood cell differential parameters analyzed by Abbott CELL-DYN Sapphire hematology analyzer. Int J Lab Hematol. 2009;31:87–96.CrossRefPubMed Hedberg P, Lehto T. Aging stability of complete blood count and white blood cell differential parameters analyzed by Abbott CELL-DYN Sapphire hematology analyzer. Int J Lab Hematol. 2009;31:87–96.CrossRefPubMed
15.
go back to reference Terstappen LW, de Grooth BG, Visscher K, van Kouterik FA, Greve J. Four-parameter white blood cell differential counting based on light scattering measurements. Cytometry. 1988;9:39–43.CrossRefPubMed Terstappen LW, de Grooth BG, Visscher K, van Kouterik FA, Greve J. Four-parameter white blood cell differential counting based on light scattering measurements. Cytometry. 1988;9:39–43.CrossRefPubMed
16.
go back to reference d’Onfrio G, Zini G, Tommasi M, Laurenti L, Vergine C, van Hove L. Quantitative bone marrow analysis using the Abbott CELL-DYN hematology analyzer. Lab Hematol. 1997;3:146–53. d’Onfrio G, Zini G, Tommasi M, Laurenti L, Vergine C, van Hove L. Quantitative bone marrow analysis using the Abbott CELL-DYN hematology analyzer. Lab Hematol. 1997;3:146–53.
17.
go back to reference National Committee for Clinical Laboratory Standards. Reference leukocyte differential count (proportional) and evaluation of instrumental methods: approved standard H20A. Wayne, PA: NCCLS; 1996. National Committee for Clinical Laboratory Standards. Reference leukocyte differential count (proportional) and evaluation of instrumental methods: approved standard H20A. Wayne, PA: NCCLS; 1996.
18.
go back to reference Stetler-Stevenson MA, Arthur D, Jabbour N, Xie XY, Molldrem J, Barrett AJ. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes. Blood. 2001;98:979–87.CrossRefPubMed Stetler-Stevenson MA, Arthur D, Jabbour N, Xie XY, Molldrem J, Barrett AJ. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes. Blood. 2001;98:979–87.CrossRefPubMed
19.
go back to reference Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Flow cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol. 2005;79:243–5.CrossRefPubMed Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Flow cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol. 2005;79:243–5.CrossRefPubMed
20.
go back to reference van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VHJ, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067–77.CrossRefPubMed van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VHJ, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067–77.CrossRefPubMed
21.
go back to reference Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom. 2005;64:9–17.CrossRefPubMed Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom. 2005;64:9–17.CrossRefPubMed
22.
go back to reference Miguel A, Orero M, Simon R, Collodo R, Perez PL, Pacios A, et al. Automated neutrophil morphology and its utility in the assessment of neutrophil dysplasia. Lab Hematol. 2007;13:98–102.CrossRefPubMed Miguel A, Orero M, Simon R, Collodo R, Perez PL, Pacios A, et al. Automated neutrophil morphology and its utility in the assessment of neutrophil dysplasia. Lab Hematol. 2007;13:98–102.CrossRefPubMed
23.
go back to reference Haschke-Becher E, Vockenhuber M, Niedetzky P, Totzke U, Gabriel C. A new high-throughput screening method for the detection of chronic lymphatic leukemia and myelodysplastic syndrome. Clin Chem Lab Med. 2008;46:85–8.CrossRefPubMed Haschke-Becher E, Vockenhuber M, Niedetzky P, Totzke U, Gabriel C. A new high-throughput screening method for the detection of chronic lymphatic leukemia and myelodysplastic syndrome. Clin Chem Lab Med. 2008;46:85–8.CrossRefPubMed
Metadata
Title
Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome
Authors
Tohru Inaba
Yoichi Yuki
Soichi Yuasa
Naohisa Fujita
Kazue Yoshitomi
Toshinori Kamisako
Kunio Torii
Toshiharu Okada
Yoshimasa Urasaki
Takanori Ueda
Kaoru Tohyama
Publication date
01-08-2011
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0892-x

Other articles of this Issue 2/2011

International Journal of Hematology 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine